01—Abstract
Summary
Summary of the 8-K filed July 31, 2024. Cited figures are marked; the original filing is the authoritative source.
Cencora, Inc. (COR) reported fiscal Q3 2024 (quarter ended June 30, 2024) results with revenue of $74.2 billiona, up 10.9% year-over-year, driven by a 12.2% increase in U.S. Healthcare Solutions revenue.
GAAP diluted EPS was $2.42b (up 3.0%), while adjusted diluted EPS rose 14.4% to $3.34. GAAP operating income was essentially flat at $672.5 million, as gross profit growth was offset by higher operating expenses, including a litigation and opioid-related expense versus a credit in the prior-year quarter. Gross margin compressed 13 basis points to 3.25%, largely due to lower-margin GLP-1 diabetes and weight-loss product sales.
Management raised adjusted diluted EPS guidance for fiscal 2024 to $13.55c–$13.65 from $13.35–$13.55, citing strong U.S. Healthcare Solutions performance and lower expected net interest expense ($170–$190 million, down from $185–$215 million). Revenue growth expectations were narrowed to approximately 12%, and adjusted free cash flow guidance was raised to $2.5–$3.0 billion. International segment expectations were tempered, with revenue growth guided to 4–6%.
The company also declared a quarterly dividend of $0.51d per share. Leadership transition is a notable item: Chairman and CEO Steven Collis will become Executive Chairman on October 1, 2024, and COO Robert Mauch will become CEO concurrently. Investors will likely focus on whether the raised guidance holds, the sustainability of U.S. segment growth amid margin pressure from GLP-1 mix, and execution under the new CEO.
02—Key points
Key Highlights
- Revenue of $74.2B, up 10.9% YoY; U.S. Healthcare Solutions revenue up 12.2% to $67.2B
- GAAP diluted EPS of $2.42 (+3.0%); adjusted diluted EPS of $3.34 (+14.4%)
- Adjusted diluted EPS guidance raised to $13.55–$13.65 from $13.35–$13.55 for fiscal 2024
- Gross margin fell 13 bps to 3.25% due to lower-margin GLP-1 product sales; GAAP operating income flat at $672.5M
- Net interest expense guidance lowered to $170–$190M; adjusted free cash flow guidance raised to $2.5–$3.0B
- Leadership transition: Steven Collis becomes Executive Chairman and Robert Mauch becomes CEO effective October 1, 2024
- Quarterly dividend of $0.51 per share declared, payable August 26, 2024
03—Questions
Frequently Asked Questions
Why did GAAP earnings grow much more slowly than adjusted earnings?
The gap reflects non-GAAP adjustments, chiefly $163.9 million of acquisition-related intangibles amortization, $42.3 million of restructuring expenses, $25.8 million of acquisition deal and integration costs, and $14.5 million of litigation and opioid-related expenses, partly offset by a $51.6 million gain from antitrust litigation settlements. Adjusted diluted EPS of $3.34 excludes these items, while GAAP diluted EPS of $2.42 includes them.
What is driving the raised fiscal 2024 guidance?
Management cited continued strong performance in U.S. Healthcare Solutions, where revenue growth guidance was narrowed to 12–13% and operating income growth raised to 11–12%, along with lower expected net interest expense. International Healthcare Solutions expectations were tapered, with revenue growth now guided to 4–6%.
Is the gross margin decline a concern for investors?
The margin decline is attributed mainly to a mix shift toward GLP-1 class products for diabetes and weight loss, which carry lower profit margins. Because U.S. Healthcare Solutions drives most of the company's revenue, investors may watch whether volume growth continues to outpace the margin dilution from this product mix.
What does the CEO transition mean for Cencora?
Steven Collis moves to Executive Chairman on October 1, 2024, and COO Robert Mauch becomes CEO at the same time. Management indicated continuity in strategy, but investors will be watching execution under new leadership.
Is the dividend and capital return outlook affected by these results?
The board declared a quarterly dividend of $0.51 per share, payable August 26, 2024. Diluted share count fell 2.1% year-over-year to 200.0 million, primarily from share repurchases, and fiscal 2024 diluted shares are expected to be under 201 million.
04—Continue